Skip to main content

Table 2 Clinical trials: Registered MSC-based treatment in ARDS

From: Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment

Identifier (status) Disease Phase Cell source Dosage Route Enrolled number Primary outcomes
NCT01775774 (Completed) ARDS 1 BM-MSCs 1, 5, 10 × 106 cells/kg I.V 9 Infusion associated adverse events
NCT02097641 (Completed) ARDS 2a BM-MSCs 1 × 107 cells/kg I.V 60 Infusion associated adverse events, numbers of death within 24 h
NCT01902082 (Unknown) ARDS 1 AD-MSCs 1 × 106 cells/kg I.V 20 Adverse events
NCT02804945 (Completed) ARDS in patients with malignancies 1 BM-MSCs 3 × 106 cells/kg I.V 20 Adverse events
ChiCTR2000029990 (Recruiting) Covid-19-related pneumonitis 1–2 BM-MSCs 1 × 106 cells/kg I.V 60 Blood oxygen saturation
NCT04355728 (Recruiting) Covid-19 patients 1–2 UC-MSCs 1 × 108 cells
(2 times)
I.V 24 Adverse events
NCT03042143 (Recruiting) Covid-19-related ARDS 1–2 UC-MSCs 1, 2, 4 × 108 cells I.V 75 Oxygenation index, adverse events
NCT04390139 (Recruiting) Covid-19-related respiratory distress 1–2 WJ-MSCs 1 × 106 cells/kg I.V 30 All-cause mortality at day 28
NCT02095444 (Recruiting) H7N9-related ARDS 1–2 MB-MSCs 1 × 107 cells/kg (4 times) I.V 20 The degree of lung injury within 14 days
NCT04416139 (Recruiting) Covid-19-related ARDS 2 UC-MSCs 1 × 106 cells/kg I.V 10 PaO2/FiO2 ratio, heart rate, respiratory rate, changes in body temperature
NCT04366063 (Recruiting) Covid-19-related ARDS 2–3 BM-MSCs 1 × 108 cells (2 times) I.V 60 Adverse events, blood oxygen saturation
NCT04371393 (Recruiting) Covid-19-related ARDS 3 BM-MSCs 2 × 106 cells/kg (2 times) I.V 300 All-cause mortality at day 30
  1. AD-MSCs adipose-derived mesenchymal stem cells, BM-MSCs bone marrow-derived mesenchymal stem cells, I.V. intravenous, MB-MSCs menstrual blood-derived mesenchymal stem cells, UC-MSCs umbilical cord-derived mesenchymal stem cells, WJ-MSCs Wharton-Jelly mesenchymal stromal cells